Zang Dong, Li Wen, Cheng Fan, Zhang Xiaobin, Rao Ting, Yu Weimin, Wei Jie, Song Yangyiyan, Jiang Wanli
Department of Clinical Laboratory, Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing 100039, China.
Department of Emergency, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Clin Chim Acta. 2022 Oct 1;535:61-67. doi: 10.1016/j.cca.2022.07.015. Epub 2022 Aug 17.
The diagnostic value of high mobility group box 1 (HMGB1) levels in patients with acute kidney injury (AKI) caused by sepsis and its relationship with disease prognosis were investigated to improve patient survival.
A total of 120 patients diagnosed with sepsis by comprehensive clinical examination were selected as the research subjects. According to the presence or absence of concurrent AKI, all patients were divided into SIAKI (50 cases with concurrent AKI) and N-AKI groups (70 cases without concurrent AKI). Sixty normal people receiving a physical examination in our hospital during the same period were divided into the control group. The diagnostic efficacy and the influences of HMGB1 on prognosis were assessed.
HMGB1 levels in the serum and urine of the control group (3.43 ± 0.73 pg/mL, 343.13 ± 51.03 pg/mL) were both lower than those of the SIAKI (14.76 ± 2.44 pg/mL, 1109.76 ± 225.66 pg/mL) and N-AKI groups (7.99 ± 1.84 pg/mL, 890.54 ± 97.76 pg/mL) (P < 0.05). HMGB1 in the serum of the SIAKI group was higher than that of the N-AKI group (P < 0.05). The sensitivity (88%), specificity (87%), accuracy (88%), and area under the curve (AUC) (0.891) of the joint diagnosis of HMGB1 in blood and urine were superior to the diagnostic effects of HMGB1 in serum (70%, 70%, 70%, and 0.701) and HMGB1 in urine (59%, 57%, 58%, and 0.677) (P < 0.05). The proportion of HMGB1 in the nonsurvivors was higher than that in the survivors (85%) and was obviously higher than that in the survivors (15%) (P < 0.05).
As a diagnostic marker of sepsis complicated with AKI, HMGB1 in serum and urine showed good application value. Serum HMGB1 could be used to assess disease prognosis with good clinical promotion.
探讨高迁移率族蛋白B1(HMGB1)水平在脓毒症所致急性肾损伤(AKI)患者中的诊断价值及其与疾病预后的关系,以提高患者生存率。
选取120例经综合临床检查确诊为脓毒症的患者作为研究对象。根据是否并发AKI,将所有患者分为脓毒症并发急性肾损伤组(SIAKI,50例并发AKI)和非急性肾损伤组(N-AKI组,70例未并发AKI)。将同期在我院进行体检的60例正常人分为对照组。评估HMGB1的诊断效能及其对预后的影响。
对照组血清和尿液中的HMGB1水平(3.43±0.73 pg/mL,343.13±51.03 pg/mL)均低于SIAKI组(14.76±2.44 pg/mL,1109.76±225.66 pg/mL)和N-AKI组(7.99±1.84 pg/mL,890.54±97.76 pg/mL)(P<0.05)。SIAKI组血清中的HMGB1高于N-AKI组(P<0.05)。血液和尿液中HMGB1联合诊断的敏感性(88%)、特异性(87%)、准确性(88%)和曲线下面积(AUC)(0.891)均优于血清中HMGB1的诊断效果(70%、70%、70%和0.701)以及尿液中HMGB1的诊断效果(59%、57%、58%和0.677)(P<0.05)。非幸存者中HMGB1的比例高于幸存者(85%),且明显高于幸存者(15%)(P<0.05)。
血清和尿液中的HMGB1作为脓毒症并发AKI的诊断标志物具有良好的应用价值。血清HMGB1可用于评估疾病预后,具有良好的临床推广价值。